A detailed history of Susquehanna International Group, LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Susquehanna International Group, LLP holds 121,200 shares of VRNA stock, worth $5.46 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
121,200
Previous 117,397 3.24%
Holding current value
$5.46 Million
Previous $1.7 Million 105.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 15, 2024

BUY
$11.48 - $17.02 $1.35 Million - $2 Million
117,397 New
117,397 $1.7 Million
Q3 2023

Nov 14, 2023

SELL
$16.3 - $22.09 $505,952 - $685,673
-31,040 Reduced 74.53%
10,607 $172,000
Q2 2023

Aug 11, 2023

BUY
$19.41 - $23.43 $808,368 - $975,789
41,647 New
41,647 $880,000
Q4 2022

Feb 14, 2023

BUY
$9.84 - $26.13 $730,944 - $1.94 Million
74,283 New
74,283 $1.94 Million
Q1 2022

May 16, 2022

SELL
$4.82 - $6.98 $59,994 - $86,880
-12,447 Reduced 40.44%
18,333 $91,000
Q4 2021

Feb 14, 2022

BUY
$3.91 - $7.08 $60,276 - $109,145
15,416 Added 100.34%
30,780 $207,000
Q3 2021

Nov 15, 2021

BUY
$5.29 - $6.35 $81,275 - $97,561
15,364 New
15,364 $84,000
Q2 2021

Aug 11, 2021

SELL
$5.72 - $9.09 $86,000 - $136,668
-15,035 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$7.08 - $9.33 $21,225 - $27,971
2,998 Added 24.91%
15,035 $126,000
Q4 2020

Feb 16, 2021

BUY
$5.51 - $8.11 $66,323 - $97,620
12,037 New
12,037 $84,000
Q1 2020

May 15, 2020

SELL
$2.16 - $7.28 $33,210 - $111,930
-15,375 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$3.7 - $6.58 $56,887 - $101,167
15,375 New
15,375 $88,000

Others Institutions Holding VRNA

About Verona Pharma plc


  • Ticker VRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,954,200
  • Market Cap $2.75B
  • Description
  • Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...
More about VRNA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.